Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Judith L. Collins"'
CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors
Autor:
J P Braselton, Michael L. Corman, Judith L. Collins, A W Schmidt, J Heym, Patricia A. Seymour, David W. Schulz, F. D. Tingley, A. Dunaiskis, S Faraci, E N Winston, Robert S. Mansbach, T Seeger, Yuhpyng L. Chen, J Sprouse
Publikováno v:
Proceedings of the National Academy of Sciences. 93:10477-10482
Here we describe the properties of CP-154,526, a potent and selective nonpeptide antagonist of corticotropin (ACTH) releasing factor (CRF) receptors. CP-154,526 binds with high affinity to CRF receptors (Ki < 10 nM) and blocks CRF-stimulated adenylat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42a0f15e8489903459ee8036cf4d276e
https://doi.org/10.1073/pnas.93.19.10477
https://doi.org/10.1073/pnas.93.19.10477
Autor:
G.W. Antognoli, J.T. Shirley, A. Marfat, C.F. Wright, Thomas J. Carty, Frank W. Rusek, J. W. Watson, J. Delehunt, B. A. Naclerio, James F. Eggler, J.S. Pillar, Herbert Sherman, E.G. Andrews, Francis J. Sweeney, K. W. Freiert, R. Breslow, C. J. Mularski, V. L. Cohan, C J Pazoles, Lawrence S. Melvin, L.A. Rappach, John B. Cheng, David B. Damon, Jeanene E. Tickner, Judith L. Collins, P. Reiche, Hiroko Masamune, M. P. Carta, James D. Eskra, Hada William Andrew, R. J. Chambers
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 5:1365-1370
The development of two novel LTD 4 receptor antagonists as clinical candidates for the treatment of asthma is described. The first generation compound, CP-80,798, was found to be a balanced 5-lipoxygenase inhibitor (5-LOI)/LTD 4 antagonist (LTD 4 -A)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a5fced5f481925dbd55bd727448996c
https://doi.org/10.1016/0960-894x(95)00225-i
https://doi.org/10.1016/0960-894x(95)00225-i
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 2:915-918
CP-99,711, identified in a screening program, displaces [125I]-glucagon from its rat liver receptor. We describe here the synthesis of this compound and its characterization as a functional glucagon receptor antagonist.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d60e5217e96580fd4a57a85070354c52
https://doi.org/10.1016/s0960-894x(00)80587-9
https://doi.org/10.1016/s0960-894x(00)80587-9
Autor:
Sanner Mark Allen, Desai Kishor A, Celeste Johnson, Jae S. Lee, Judith L. Collins, Audrey R. Dunaiskis, W. Stephen Faraci, Cecilia C. Di Prete, Angela Trozzi, Thomas Allen Chappie, Patricia A. Seymour, Jean Morrone, David B. Duignan, Stevin H. Zorn, Mark J. Majchrzak, Jackson Elisa Rose, Fliri Anton F J
Publikováno v:
Bioorganicmedicinal chemistry letters. 8(7)
A series of novel, potent and selective pyrido[1,2-a]pyrazine dopamine D4 receptor antagonists are reported including CP-293,019 (D4 Ki = 3.4 nM, D2 Ki > 3,310 nM), which also inhibits apomorphine-induced hyperlocomotion in rats after oral dosing.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e87bcf9121789661fcccc9f11a1f8abb
https://pubmed.ncbi.nlm.nih.gov/9871530
https://pubmed.ncbi.nlm.nih.gov/9871530
Autor:
Faraci Ws, Brooks E, Robert S. Mansbach, Anne W. Schmidt, Randall James Gallaschun, A. Dunaiskis, David W. Schulz, Michael L. Corman, Yuhpyng L. Chen, Winter Sm, Judith L. Collins
Publikováno v:
Journal of medicinal chemistry. 40(11)
The syntheses of a centrally active nonpeptide CRF1 receptor antagonist 2, butylethyl[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo [2,3-d]pyrimidin-4-yl]amine (CP-154,526), and its analogs 11-14 and [3H]-2 are reported. The in vitro CRF1 recepto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4765f47d370d4d3c780fa1554bd44cda
https://pubmed.ncbi.nlm.nih.gov/9171885
https://pubmed.ncbi.nlm.nih.gov/9171885